Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
Author
Paz-Ares, L.
Reinmuth, N.
Hotta, K.
Trukhin, D.
Poltoratskiy, A.
Verderame, F.
Havel, L.
Bondarenko, I.
Losonczy, G.
Conev, N. V.
Broadhurst, H. L.
Dalvi, T.
Jiang, H.
Goldman, J. W.
Chen, Y.
Statsenko, G.
Hochmair, M. J.
ÖZGÜROĞLU, Mustafa
Ji, J. H.
Voitko, O.
Metadata
Show full item recordCollections
- Makale [91033]